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Abstract: Prostate cancer (PCa) is the most common malignancy in men and is the leading cause of
cancer-related male mortality. A disulfide cyclic peptide ligand [CTVRTSADC] 1 has been previously
found to target extra domain B of fibronectin (EDB-FN) in the extracellular matrix that can differentiate
aggressive PCa from benign prostatic hyperplasia. We synthesized and optimized the stability of
ligand 1 by amide cyclization to obtain [KTVRTSADE] 8 using Fmoc/tBu solid-phase chemistry.
Optimized targeting ligand 8 was found to be stable in phosphate buffered saline (PBS, pH 6.5,
7.0, and 7.5) and under redox conditions, with a half-life longer than 8 h. Confocal microscopy
studies demonstrated increased binding of ligand 8 to EDB-FN compared to ligand 1. Therefore, we
hypothesized that the EDB-FN targeted peptides (1 and 8) conjugated with an anticancer drug via a
hydrolyzable linker would provide selective cytotoxicity to the cancer cells. To test our hypothesis,
we selected both the normal prostate cell line, RWPE-1, and the cancerous prostate cell lines, PC3,
DU-145, LNCaP, and C4-2, to evaluate the anticancer activity of synthesized peptide–drug conjugates.
Docetaxel (Doce) and doxorubicin (Dox) were used as anticancer drugs. Dox conjugate 13 containing
disulfide linkage showed comparable cytotoxicity versus Dox after 72 h incubation in all the cancer
cell lines, whereas it was found to be less cytotoxic on RWPE-1, suggesting that it can act as a
Dox prodrug. Doce conjugate 14 was found to be less cytotoxic in all the cell lines as compared to
drug alone.
Keywords: antiproliferative assay; conjugation; docetaxel; doxorubicin; extra domain B; fibronectin;
Fmoc/tBu; peptide–drug conjugate; prostate cancer; solid-phase synthesis; targeting
1. Introduction
Prostate cancer (PCa) is the most common form of cancer in males and the second leading cause
of death after lung cancer in the United States. According to the American Cancer Society, it is also the
first leading cause of cancer mortality in males aged 65 and older in the United States [1]. There are
several treatment options for prostate cancer patients, which depend on the clinical risk assessment at
the time of diagnosis, including tumor stage and grade, but also patient age and health. High-risk local
disease is routinely addressed by local treatment with curative intent, such as radical prostatectomy
followed by adjuvant radiation or androgen ablation therapy. Unfortunately, a fraction of patients
(~20%) will progress to more aggressive disease, manifested by a metastatic spread of primary tumor
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cells, which in the United States results in a mortality rate of ~30,000 individuals per year [2]. Recurrent
systemic disease, including metastatic castration resistance prostate cancer (mCRPC) after androgen
ablation therapy, is typically treated with chemotherapy, most notably with docetaxel (Doce) and
cabazitaxel [3,4]. The anthracycline doxorubicin (Dox) as a main chemotherapeutic drug for prostate
cancer remains in the exploratory setting, while its synthetic chemical modifications, such as the
anthracenedione (mitoxantrone) is in clinical use [5]. Regardless of the chemotherapeutic drug in
use, whether in single or in combinatorial regimens, the major problem of off-target effects leads to
substantial morbidity due to side effects. This has led to multiple lines of research into targeting
strategies, including the use of liposomes and nanoparticles [6,7]. We have previously reported the
synthesis of cell-penetrating peptide–drug conjugates for the delivery of anticancer drugs [8]. Targeted
therapy could deliver the cytotoxic or therapeutic molecules to cancer cells, thereby minimizing
exposure to normal cells. This promises to reduce the side effects associated with drug-based systemic
therapies [9]. The use of tumor-specific or homing peptides as an example of targeted delivery in
cancer was shown by Ruoslahti et al. [10]. A heightened efficiency of the delivery of a cytotoxic agent
may also counteract the eﬄux of drugs due to multidrug resistance pumps. Hence, tumor targeting
with enhanced selectivity should be more beneficial for an effective therapeutic outcome. Several
ligands have been reported for targeting cytotoxic or chemotherapeutics molecules, such as monoclonal
antibodies, peptide hormones, receptor-binding ligands, aptamers, oligosaccharides, vitamins, folic
acids, nanoparticles, and DUPA [11]. However, most of these targeting ligands lack specificity for tumor
cells, which in the clinical setting, is expected to lead to side effects due to their effect on non-malignant
normal cells. Therefore, there is a need to develop more tumor-specific targeting modalities.
The extracellular matrix (ECM) is a microenvironment within all types of tissues and organs
containing non-cellular components such as collagen, fibroblasts (which ARE cells), fibronectins (FNs),
and blood vessels as a part of the basal lamina for the support of epithelial cells [12]. The ECM is
responsible for adhesion, migration, cell-to-cell communication, homeostasis, growth, and proliferation
of the cells, and thus contributes significantly to metastasis of tumors [13]. In malignant tumors, the
microenvironment exhibits unusual overexpression of cancer-related proteins, such as the extra-domain
B fibronectin (EDB-FN). EDB-FN is a high-molecular glycoprotein that mediates cell adhesion and
migration [14]. EDB-FN has been reported to be found around new blood vessels of tumors and
provides a promising specific biomarker for cancer [15–17]. Therefore, EDB-FN could be used for
targeted therapy in PCa. For example, Zheng et al. showed the use of a specific peptide ligand
[CTVRTSADC] 1, which targets EDB-FN in PCa (Figure 1). This ligand was used in the diagnosis
of later stages of PCa, differentiating them from benign hyperplasia. Later, ligand 1 was used as a
targeted contrast agent in MRI application for PCa [18]. Therefore, peptide ligand 1 could be selected
as a potential targeting ligand to develop targeted chemotherapeutics for PCa.
The rationale for the selection of peptides as targeting ligands is due to the fact that peptides
are highly selective, safer, and tolerable agents in vivo. The specificity of the peptide ligand for its
target could be used to deliver an anticancer drug to their target in cancer. Thus, we hypothesized
that the conjugates of EDB-FN targeted peptide ligand with anticancer drugs containing a suitable
linker will release the anticancer drug in the PCa and minimize side effects in normal cells. Here in this
study, we report the synthesis and modification in peptide ligand 1, developing peptide-anticancer
drug conjugates, their characterization, stability, and in vitro assays against a panel of PCa and normal
prostate cell lines.
2. Results and Discussion
2.1. Chemistry
We synthesized two different cyclic peptide EDB-FN targeting [CTVRTSADC] 1 and [KTVRTSADE]
8 (Figure 1) using solid phase peptide chemistry and used for the conjugation with anticancer drugs.
Two anticancer drugs, Dox and Doce, were used for the conjugation. We adopted six carbon long
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aminohexanoic acid to provide spacer followed by cathepsin-B enzyme sensitive linker to release the
drug moiety efficiently. Two types of dipeptide cathepsin-B enzyme sensitive linkers including valine
and citrulline (VCit) and phenylalanine and lysine (FK) were adopted in the early phase of the study,
but later a tetrapeptide linker with better release profile involving glycine, phenylalanine, leucine, and
glycine (GFLG) was chosen. To facilitate drug attachment, hydrazone, disulfide, and thiomaleimide
linkages were used. To provide a spacer for better recognition of the cathepsin-B sensitive linker,
dipeptide of glycine was attached on hydrazone linkage, or additional cysteine was attached on the
N-terminal to facilitate disulfide linkage.
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Figure 1. he ical structures of peptide ligands 1 and 8.
2.1.1. Synthesis of Targeting Ligand
Selected peptide ligand [CTVRTSADC] 1 contained a disulfide bridge between C- and N-terminal
cysteine residues and was generated after the first-generation screening of phage display library
bound to EDB-FN as previously reported [15]. Using this peptide, we designed the peptide-linker
hydrazine-glutarate-GG-FK-C6-[CTVRTSADC] 5 and hydrazine-glutarate-GG-VCit-C6-[CTVRTSADC]
6 containing a cathepsin-sensitive linker (Scheme 1).
This disulfide linkage in targeting peptide 1 may be hydrolyzed in vivo due to the presence of
glutathione or under physiological condition, which may reduce targeting efficiency of the ligand.
Alternatively, we designed a more stable analog of ligand 1, which contains lactam cyclization
between lysine and glutamic side chain in place of cysteine amino acids. Therefore, two cyclic
peptides [CTVRTSADC] 1 and [KTVRTSADE] 8 were synthesized using standard Fmoc/tBu solid-phase
peptide synthesis (SPPS) on Rink amide resin as solid support. All the peptides were purified by
preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and analyzed by
Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass spectroscopy (see
supporting material). Most of the peptides showed an [M + H]+ peak in the spectra, which is due to
the presence of the protonated amino group. We also observed mass fragments presumably because of
the breakdown of disulfide linkage to thiol (SH) groups when higher laser energy was used in the
MALDI-TOF mass spectroscopy.
2.1.2. Synthesis of Peptide-Linker Conjugates
A spacer of six carbon (C6) was included using Fmoc-aminohexanoic acid (Fmoc-Ahx-OH) in
the design of peptide–drug conjugates to allow targeting ligand to recognize their binding motif.
The release of drug from the conjugates was expected using a suitable linker. A cathepsin enzyme
based linker was selected to allow the drug to be released at the site of the tumor [19]. Cathepsin-based
linkers are dipeptides (FK, VCit) or tetrapeptides (GFLG), which release drug moiety efficiently from
the conjugate as previously reported [20–22].
Scheme 1 depicts the synthesis of various cathepsin linkers in the peptide 1 cyclized through a
disulfide linkage. A spacer of two glycine amino acids was added in the peptide sequence to avoid
any steric hindrance for enzyme recognition of the linker. Furthermore, a hydrazine group was also
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Scheme 1. Synthesis of hydrazine-glutarate-GG-FK-C6-[CTVRTSADC] 5 and hydrazine-glutarate-
GG-VCit-C6-[CTVRTSADC] 6.
Modified peptide ligand (KTVRTSADE) 8 was assembled on the resin with the modification
of reported methodology of ligand 1 [18]. Scheme 2 depicts the synthesis of 8 that has lysine and
glutamic acid residues instead of cysteine residues. Peptidyl resin went through lactam cyclization and
conjugated with a linker. The orthogonal protected groups used during the synthesis for lysine and
glutamic acid were 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) and 2-phenylisopropyl
(Phipr), respectively. The protected linear version of peptide 8 was assembled on Rink amide resin
followed by selective deprotection of Fmoc and Phipr group in the side chains. Lactam cyclization
afforded side-chain cyclized intermediate peptide. After cleavage of a part of the resin, the calculated
mass of 8 was 986.5145 [M]+ that was consistent with experimental value 987.2699 [M + H]+. Scheme 2
shows the synthesis of the linker, spacer, and targeting moiety in peptide 9. Cysteine residue was
incorporated at the N-terminal for functionalization in drug conjugation.
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Doxorubicin (Dox) and ocetaxel (Doc re selected as model anti ancer drugs for the
conjugation with the synthesized linker-E e tides to form compound Dox-s-s- FLG-C6-
[KTVRTSADE] 13 and Doce-βA-thioether-CGFLG-C6-[KTVRTSADE] 14. Dox and Doce have been
widely used in chemotherapy against several cancers, including PCa [23]. The intermediate compound
Dox-disulfide-pyridine was prepared by reaction of Dox with 2-iminothiolane followed by activation of
the sulfhydryl group by reacting with dithiodipyridine at the room temperature (Scheme 3). Similarly,
Doce was functionalized with Fmoc-β-alanine-OH to reduce the steric hindrance in the reaction with
the linker-EDB pepti e. The C2’ hydroxyl group in the Doce has been previously reported to be
more reactive as compared to other hydroxyl groups in the compound. The other hydroxyl groups
have show to have low chemical reactivity due to the presence of more steric hindra ce [24–26].
After Fmoc removal, the crude esterified Doce-β-alanine was purified using RP-HPLC. The purified
compound showed one major peak with expected mass and was concentrated to use for the next
reaction. A bifunctional linker sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate)
(sulfo-SMCC) was used to facilitate conjugation of Doce-β-alanine-NH2 to form Doce-β-alanine-SMCC
11, which was utilized in the conjugation with peptide 9 (Scheme 4). In another strategy, ketone group
at the C13 position in the Dox was reacted under mildly acidic condition with the hydrazine group
present at the EDB peptide-linker 6 to form hydrazone linkage in conjugate 12 as shown in Scheme 5.
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2.1.4. Conjugation of Anticancer Drugs with Peptides
Three peptide–drug conjugated compounds (12, 13, and 14) were synthesized (Scheme 5). In the
first reaction, Dox was reacted under a mild acidic condition with hydrazine-glutarate-GG-VCit-
C6-[CTVRTSADC] 6 for 20 h at room temperature to afford the Dox–hydrazone peptide conjugate
12 (Scheme 5). In the second attempt, Dox-activated disulfide compound 10 was reacted with
C-GFLG-C6-[KTVRTSADE] 9 to afford Dox-s-s-C-GFLG-C6-[KTVRTSADE] 13. In the third attempt,
the Doce-β-alanine-SMCC 11 was reacted with sulfhydryl group in 9 using phosphate buffered saline
(PBS, pH 8.0) containing 20 mM EDTA for 17 h to form Doce-thioether-CGFLG-C6-[KTVRTSADE]
13. All the conjugates were purified and characterized using RP-HPLC and MALDI-TOF mass
spectrometry, respectively. Table 1 shows the chemical analysis and details of synthesized peptides
and peptide–drug conjugates.
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Table 1. The sequences of extra domain B of fibronectin (EDB-FN) targeting peptides and peptide–drug conjugates.
Peptide Peptide Sequence Chemical Formula Exact Mass Found (M/Z)
1 [CTVRTSADC] C35H62N13O14S2 952.3980 952.4786, [M + H]+
5 Hydrzb-Glutrtb-GG-FK-C6a-[CTVRTSADC] C65H111N21O21S2 1585.7704 1585.5270, [M +H]+
6 Hydrzb-Glutrtb-GG–VCita–C6a-[CTVRTSADC] C61H109N22O22S2 1565.7527 1565.5920, [M + H]+
8 [KTVRTSADE] C40H71N14O15 987.5223 987.2699, [M + H]+
9 CGFLG-C6a-[KTVRTSADE] C68H113N20O21S 1577.8110 1577.6815, [M]+
10 Dox-s-s-Pyridine C36H40N3O11S2 754.2104 754.4053, [M + H]+
11 Doce-βA-SMCC C58H72N3O18 1098.4811 1098.1675, [M + H]+
12 Dox-hydrzc-Glutrtb–GG–VCita–C6a-[CTVRTSADC] C88H136N23O32S2 2090.9003 2090.7130, [M + H]+
13 Dox-s-s-CGFLG-C6a-[KTVRTSADE] C99H150N22O32S2 2223.0227 2222.3398, [M +H]+
14 Doce-βA-thioether-CGFLG-C6a-[KTVRTSADE] C126H184N23O39S 2675.2842 2675.8490, [M + H]+
15 GFLG-C6a-[CTVRTSADC] C60H100N18O19S2 1440.6615 1440.5944, [M + H]+
16 GFLG-C6a-[KTVRTSADE] C65H109N19O20 1475.8096 1475.8738, [M + H]+
17 FAM-GFLG-C6a-[CTVRTSADC] C81H111N18O25S2 1799.7249 1799.928, [M + H]+
18 FAM-GFLG-C6a-[KTVRTSADE] C86H118N19O26 1832.8495 1832.3740, [M + H]+
19 CGFLG-C6a-[CTVRTSADC] C63H106N19O20S3 1544.6863 1544.1794, [M + H]+
Cyclic peptides are shown using the [] bracket. aUnnatural amino acids denominated by βA, C6, and Cit, which
represent beta-alanine, 6-aminohexanoic acid, and citrulline, respectively. FAM stands for 5(6)-carboxyfluorescein.
bHydrazine and glutarate linkers are abbreviated as Hydrz and Glutrt, respectively. cHydrazone.
2.1.5. Conjugation of 5(6)-Carboxyfluorescein (FAM) Motif with Peptides
Peptides 15 and 16 containing linker and targeting ligand (1 and 8, respectively) were conjugated
with a carboxyfluorescein dye to determine whether ligand 8 showed higher localization and targeting
toward EDB-FN as compared to its disulfide cyclized counterpart 1. A 5(6)-carboxyfluorescein
diisobutyrate (CFDI) was coupled to N-terminus of glycine in both peptides (15 and 16) in the presence
of PyAOP, HOAt, and DIPEA using anhydrous DMF. Fluorescent-tagged peptides (17 and 18) were
purified and characterized using RP-HPLC and MALDI mass spectrometry, respectively (Scheme 6).
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 23 
 
 
1. CFDI, HOAt, PyAOP, DIPEA
2. 20% Piperidine/ DMF (v/v)
3. TFA/TIS/H2O
4. 10% DMSO
HN O
OH
H
N
O NH
O NH
O
NHO
NH
O
N
H
O
HN
O
HNH2N
O
N
H
NH
NH2
OH
O
OH
HO
OHN
N
H
H
NN
H
H
NN
H O
O
O
O
O
HN O
OH
H
N
O NH
O
NH
O
NHO
N
H
O
N
H
O
H
N
O
S
HNH2N
S
O
N
H
NH
NH2
OH
O
OH
HO
O
N
H
H
NN
H
H
NN
H
O
O
O
O
O
O
HO
OH
O
O
O
O
HO
OH
O
O
16
17
18
1. CFDI, HOAt, PyAOP, DIPEA 
2. 20% Piperidine/DMF (v/v)
3. TFA/TIS/H2O
Rink amide resin
N
H
H
NN
H
H
NH2N
O
O
O
O
O
Fmoc/tBu Solid-Phase Synthesis
Rink amide resin
Fmoc/tBu Solid-Phase Synthesis
15
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
O
O
O
OO
O
OO
O
NH
HN NH
O
O
O
O
S S
H
N
trt
trt
tButBu
Pbf
tBu
O
tBu
O
N
H
H
NN
H
H
NH2N
O
O
O
O
HN O
O
H
N
O NH
O NH
O
NHO
NH
O
N
H
O
H
N
O
HN
H
N
O
N
H
NH
HN
O
O
O
O
OHN
PbftBu
tBu
tBu
tBu
 
Scheme 6. Conjugation of FAM with the peptide targeting moiety through a hydrolyzable linker. 
2.1.6. Stability and Hydrolysis 
The stability of selected synthesized doxorubicin-peptide conjugate 13 was evaluated under 
different physiological conditions to mimic the in vivo environment, such as different pH, under 
redox condition, and in the human serum as depicted in the Figures 1–4. Conjugate 13 showed high 
stability in PBS with a half-life of ~10 h in pH values ranging from 6.5 to 7.4 (Figure 2). It also appears 
that the dox peptide conjugate 13 is stable at pH tested from 6.5 to 7.4. No drastic differences observed 
between stability in three different physiological pHs. Furthermore, conjugate 13 were treated with 
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when incubated with 12 equivalents of DTT that confirms the release of Dox from disulfide linkage 
due to redox conditions. Similarly, the targeting peptides which consist of disulfide cyclization 
(peptide 1) and lactam cyclization (peptide 8) were incubated in the redox condition. In the presence 
of DTT, the targeting peptide ligand 1 behaved as expected and released reduced disulfide linkage 
quickly. During HPLC analysis of the ligand, it was found to be too difficult to separate the linear 
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insight. Peptide 1 was reduced to its linear form that has a slightly higher mass because of the 
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increasing its mass by 2 Da in high-resolution MALDI-TOF mass spectroscopy (Figure 5). However, 
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2.1.6. Stability and Hydrolysis
The stability of select d synthesized oxorubicin-peptide co j aluated under
different physiological conditions to mimic the in vivo environme t, such as different pH, under redox
condition, an in the human ser as depicted in the Figures 1–4. Conjugate 13 showed high stability
in PBS with a half-life of ~10 h in pH values ranging from 6.5 to 7.4 (Figure 2). It also appears that
the dox peptide conjugate 13 is stable at pH tested from 6.5 to 7.4. No drastic differences observed
between stability in three different physiological pHs. Furthermore, conjugate 13 were treated with
redox condition using dithiothreitol (DTT) to confirm the release of Dox from conjugate 13 that allows
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the free drug becomes bioactive. Figure 3 shows the hydrolysis of conjugate 13 within 2.6 min when
incubated with 12 equivalents of DTT that confirms the release of Dox from disulfide linkage due to
redox conditions. Similarly, the targeting peptides which consist of disulfide cyclization (peptide 1)
and lactam cyclization (peptide 8) were incubated in the redox condition. In the presence of DTT, the
targeting peptide ligand 1 behaved as expected and released reduced disulfide linkage quickly. During
HPLC analysis of the ligand, it was found to be too difficult to separate the linear and cyclic forms
of CTVRTSADC, so MALDI mass spectrometry was used to obtain a qualitative insight. Peptide 1
was reduced to its linear form that has a slightly higher mass because of the addition of two hydrogen
atoms to the reduced disulfide bond into two sulfhydryl groups thereby increasing its mass by 2 Da
in high-resolution MALDI-TOF mass spectroscopy (Figure 5). However, peptide 8 was stable under
reducing conditions as expected (Figure 4).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 23 
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Figure 2. Conjugate 13 in PBS at different pH. The percent remaining of conjugate 13 was quantified
using the area under the curve (AUC) in analytical HPLC.
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The experiment was done in PBS at pH 7.4. The per ent remaining was quantified using the AUC,
and the tre dline equation gives the half-life of 2.6 in with an R2 of 0.98. Fitting was do e online
using MyCurveFit.
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Figure 4. Stability of peptide 8 ([KTVRTSADE]) in pH 7.4 PBS with DTT. The percent remaining was
calculated from the AUC.
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Figure 5. Peptide 1 before (a) and after 5 mi ( bation with DT . T e igher mo ecular weight
shows a full reduction of pe tide 1 to the linear co terpart of (CTVRTSADC) with n 5 min.
Dox–peptide conjugate 13 s a quick degr datio in hu an serum at 37 ◦C (Figure 6).
The data sho s that conjugate 13 has a half-life of approximately 11.8 min in 25% human serum. There
was no visible difference in the shape of the percentage remaining vs. time plot when performed using
a higher concentration of conjugate 13. Thus, it was speculated that the rate of the reaction increased
proportion lly whe a higher conce tratio (100 µM) of D x–peptide was used. This indicates that the
reaction was likely to be first-order with regard to Dox–peptide 13 under these conditions. Usually,
peptides and peptide–drug conjugates have a very wide range of serum stabilities ranging from less
than min in human serum to over 200 min leading to an undetectable amount of degradation [27].
Conjuga e 13 showed a half-life f 11.8 mi , w ich displays that th s peptide–drug conjugat , although
does not have outstanding stability, it may have time to yield an effect on cancer cells in vivo.
Furthermore, the hydrolysis of peptide–drug conjugate 13 containing a cathepsin B cleavable
linker was evaluated using in vitro assay as reported [28]. Figure 7 shows that cathepsin B enzyme
recognizes GFLG linker in the conjugate 13 and cleaves it within 5 min of incubation time. Dox–peptide
conjugate 13 showed a peak with the retention time of 34 min. After incubation with serum, the
compound was hydrolyzed and showed different peaks. The peak with a retention time around
30.5 min was found to be dox conjugated with a couple of amino acid residues. The free doxorubicin
was found with the retention time of 30 min (Supporting information, Figure S1). The peak at 30.5
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min showed absorption at 490 nm and with some at 214 nm, which demonstrates amide linkage for
conjugated amino acids. Therefore, the peak at 30.5 min was likely to be with Dox conjugated with a
couple of amino acids. This enzymatic reaction occurred too fast to assess the kinetic nature of the
reaction. However, it demonstrated the utility of the cathepsin B-sensitive linker in conjugate design.
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2.2. Cell-Based Assays
2.2.1. Peptide Cytotoxicity
To evaluate the cytotoxicity of the synthesized compounds, we selected both a normal prostate
cell line (prostate epithelial cells transformed by HPV, RWPE-1) and cancerous prostate cell lines
(LNCaP, PC3, DU-145, and C4-2) [29]. LNCaP is an indolent form. DU-145 is a moderatetly
metastatic cell form as compared to PC3, which is an aggressive form of PCa with a high
metastatic potential [30]. C4-2 cells were originally derived from LNCaP xenografts grown in
castrated mice exhibiting androgen-independence and were found to have elevated expression of
EDB-FN, which would help explore the targeting of peptide conjugate [31]. Evaluation of the
cytotoxicity of synthesized targeting peptides hydrazine-glutarate-GG-FK-C6-[CTVRTSADC] 5 and
hydrazine-glutarate-GG–VCit–C6-[CTVRTSADC] 6 as compared to peptide C-GFLG-C6-[KTVRTSADE]
9 were performed on different timelines (24, 48, and 72 h) using a panel of cell lines such as RWPE-1,
LNCaP, PC3, DU-145, and C4-2 as depicted in Figure S2. These peptides were used in the conjugation
of anticancer drugs connecting through three different types of peptidic cathepsin linkers such as
phenylalanine lysine (FK), valine citrulline (VCit), and glycine phenylalanine leucine glycine (GFLG).
These peptides were used to perform a cytotoxicity assay at a selected concentration of 5 µM as used
previously in screening peptide–drug conjugates in different cancer cell lines [8]. Figure S2 (supporting
information) showed that peptides 5, 6, 9 did not show any significant cytotoxicity to normal human
prostate epithelial cells (RWPE-1), and cancerous prostate cell lines LNCaP, C4-2, PC3, and DU-145
after 72 h. These results are not surprising since the targeting peptides are not expected to have any
intrinsic antiproliferative activity.
The determination of cytotoxicity of peptide C-GFLG-C6-[KTVRTSADE] 9 and selected peptide–drug
conjugate Dox-s-s-CGFLG-C6-[KTVRTSADE] 13 were performed in PC3 cell line after 2 h of incubation
using positive control (doxorubicin) and negative control (5% DMSO). Different concentrations (0.01,
0.1, 1, 10, and 100 µM) of Dox, peptide 9, and conjugate 13 were prepared in 5% DMSO and used in
the screening in the PC3 cell line after incubation for 2 h to observe the cytotoxicity of targeting peptide
9 in comparison to parent drug Dox and its conjugate 13 (Figure 8). The conjugate 13, peptide 9, and
Dox showed no significant toxicity at or below 10 µM, possibly due to the shorter incubation time of 2
h. Dox usually requires 24 to 72 h incubation time to show any cytotoxicity at a lower concentration.
The targeting peptide 9 did not show any toxicity up to the concentration of 100 µM.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 13 of 23 
 
information) showed that peptides 5, 6, 9 did not show any significant cytotoxicity to normal human 
prostate epithelial cells (RWPE-1), and cancerous prostate cell lines LNCaP, C4-2, PC3, and DU-145 
after 72 h. These results are not surprising since the targeting peptides are not expected to have any 
intrinsic antiproliferative activity. 
The determination of cytotoxicity of peptide C-GFLG-C6-[KTVRTSADE] 9 and selected peptide–
drug conjugate Dox-s-s-CGFLG-C6-[KTVRTSADE] 13 were performed in PC3 cell line after 2 h of 
incubation using positive control (doxorubicin) and negative control (5% DMSO). Different 
concentrations (0.01, 0.1, 1, 10, and 100 µM) of Dox, peptide 9, and conjugate 13 were prepared in 5% 
DMSO and used in the screening in the PC3 cell line after incubation for 2 h to observe the cytotoxicity 
of targeting peptide 9 in comparison to parent drug Dox and its conjugate 13 (Figure 8). The conjugate 
13, peptide 9, and Dox showed no significant toxicity at or below 10 µM, possibly due to the shorter 
incubation time of 2 h. Dox usually requires 24 to 72 h incubation time to show any cytotoxicity at a 
lower concentration. The targeting peptide 9 did not show any toxicity up to the concentration of 100 
µM.  
 
Figure 8. Cytotoxicity of peptide 9, conjugate 13 (Dox-s-s-CGFLG-C6-[KTVRTSADE]) and Dox on a 
PC3 prostate cancer cell line after two hours of incubation at various concentrations. 
The conjugates 13 and 14 were tested at 5 µM concentration using both positive and negative 
controls in all the four cell lines after 72 h incubation. Figure 9 depicted that Dox conjugate 13 was 
moderately toxic with a reduced cell proliferation to a range of 25–35% as compared to Dox which 
reduced cell proliferation in the range of 20–34% for all selected four cell lines. However, it was 
interesting to observe that Doce conjugate 14 was almost nontoxic (cell proliferation within the range 
of 89–96%) in all the cell lines as compared to Doce alone which reduced the cell proliferation in the 
range of 54–61% (Figure 9). The comparable potency of Dox conjugate 13 versus Dox suggests the 
possible reduction of disulfide linkage, and release of an active form of Dox from the conjugate after 
the cellular uptake. As described above in the stability studies, compound 13 was found to be 
unstable under redox conditions, and in the presence of cathepsin B. On the other hand, the inactivity 
of conjugate 14 is possibly due to lack of hydrolysis to get an active drug, Doce. Conjugate 14 does 
not have disulfide linkage and it is possible that ester bond of the secondary alcohol and amide bond 
do not undergo fast hydrolysis.  
0.0
20.0
40.0
60.0
80.0
100.0
120.0
5%DMSO 10 nM 100 nM 1 μM 10 μM 100 μM
C
el
l v
ia
bi
lit
y 
(%
)
Concentration of compounds
9
Dox alone
13
Figure 8. Cytotoxicity of peptide 9, conjugate 13 (Dox-s-s-CGFLG-C6-[KTVRTSADE]) and Dox on a
PC3 prostate cancer cell line after two hours of incubation at various concentrations.
Int. J. Mol. Sci. 2019, 20, 3291 12 of 21
The conjugates 13 and 14 were tested at 5 µM concentration using both positive and negative
controls in all the four cell lines after 72 h incubation. Figure 9 depicted that Dox conjugate 13 was
moderately toxic with a reduced cell proliferation to a range of 25–35% as compared to Dox which
reduced cell proliferation in the range of 20–34% for all selected four cell lines. However, it was
interesting to observe that Doce conjugate 14 was almost nontoxic (cell proliferation within the range of
89–96%) in all the cell lines as compared to Doce alone which reduced the cell proliferation in the range
of 54–61% (Figure 9). The comparable potency of Dox conjugate 13 versus Dox suggests the possible
reduction of disulfide linkage, and release of an active form of Dox from the conjugate after the cellular
uptake. As described above in the stability studies, compound 13 was found to be unstable under
redox conditions, and in the presence of cathepsin B. On the other hand, the inactivity of conjugate 14
is possibly due to lack of hydrolysis to get an active drug, Doce. Conjugate 14 does not have disulfide
linkage and it is possible that ester bond of the secondary alcohol and amide bond do not undergo
fast hydrolysis.
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Figure 9. Cell viability of peptide 9, Dox, Doce, Dox–peptide conjugate 13, and Doce–peptide conjugate
14 at 5 µM on prostate epithelial and PCa cell lines (RWPE-1, PC3, LNCap, Du-145) after 72 h using
MTS assay.
Furthermore, to evalu te the effect of selectivit f s thesized conjugates containing targeting
ligand, the cells were t at d with TGF-β for 3 da i uce overexpression of EDB-FN as eported
and assayed using cell viability assay for 24–72 h [3 . lso, an equimolar amount of the physical
mixture of drug and peptides were evaluated to determine the potency of these compounds in TGF-β
positive treated cells. C4-2 cell line was used with and without TGF-β treatment (Figure 10a,b)
as it was reported to show overexpression of EDB-FN [31]. C4-2 cells were derived from human
prostate adenocarcinoma LNCaP cells. Figure 10a showed an increase in the cytotoxicity of Dox and
Dox/peptide 9 physical mixture as compared to the conjugate 13 over an incubation period of 24 h
to 72 h. Conjugates 13 and 14 were found to be less cytotoxic as compared to drug alone in 24–72 h.
These cells were not treated with TGF-β, s very minimal or no overexpression of EDB-FN. Figure 10b
showed the effect of overexpressi n of EDB-FN in the cell viabili y. There was no observed effect of
TGF-β treatment for th cytotoxicity of Dox and physical mixture of Dox/peptide 9 on th c ll viability
as compared to the TGF-β untreated cell lines. However, conjugate 13 showed a decrease in cell
viability by 17% after 72 h as compared to untreated cell lines. Similarly, Doce and Doce conjugate
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14 showed decrease in cell viability by 16 and 10%, respectively, after 72 h. The physical mixtures of
Doce/peptide 9 showed a decrease in cell viability by 16% as compared to untreated cells.
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2.2.2. Confocal Microscopy of the Fluorescently Tagged Compounds 17 and 18
To evaluate the comparative EDB-FN binding capability of disulfide cyclized peptide 1 and its
more stable analog 8, we prepared the corresponding FAM-conjugated fluorescent tagged derivatives,
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namely peptide 17 and 18, respectively. C4-2 cells were used for this assay due to overexpression
of EDB-FN [31]. Expression of EDB-FN was confirmed using PCR. The C4-2 cells were incubated
with the FAM-conjugated peptide 17 and 18 dissolved in the cell culture media for 12 h. Figure 11
shows the confocal images of EDB-FN stained cells without any peptide (a, control), incubated with
peptide 17 (b) and peptide 18 (c) respectively at 60× magnification. As it is evident from Figure 11,
peptide 18 showed notably higher binding and colocalization for EDB-FN as compared to peptide
17. A binary contrast quantification showed a significant increase of 48% in the peptide-stained area
in cells incubated with peptide 18 compared to that of peptide 17. These images reflect binding of
peptide 17 and 18 to EDB-FN, which includes linkers and spacer, which presumably did not change
the affinity of ligands for EDB-FN. The enhanced binding of peptide 18 over peptide 17 was speculated
to be due to the higher stability of ligand 18.
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3. Materi ls and Methods
3.1. Chemistry
All amino acids and resins were purchased from AAPPTec LLC (Louisville, KY, USA), Chem-Impex
International Inc. (Wood Dale, IL, USA), and CEM Corporation (Matthews, NC, USA). All organic
solvents were purchased from Millipore Sigma Corporation (St. Louis, MO, USA), Fischer Scientific
(Pittsburgh, PA, USA), and Gyros Protein Technologies, Inc (Tucson, AZ, USA). Anticancer agents
Doxorubicin (Dox) and Docetaxel (Doce) were purchased from LC laboratories (Woburn, MA, USA).
Masses of intermediate and final pr ducts were confirmed by high-resolution matrix-assisted laser
desorption/ ionization time- f-flight (MALDI-TOF) mass spectrometer from Bruker Inc. (GT 0264,
Billerica, MA, USA) or Applied Biosystems (4800 MALDI TOF/TOF Analyzer, Foster City, CA,
USA). Intermediate and final compounds were purified by reversed-phase high-performance liquid
chromatography (RP-HPLC) from Shimadzu (Prominence, Columbia, MD, USA) using a gradient
system of acetonitrile and water with 0.1% trifluoroacetic acid using reverse phase C18 column
(XBridge BEH130 Prep C18), from Waters Corporation (Milford, MA, USA). 5(6)-Carboxyfluorescein
diisobutyrate (CFDI) was used to synthesize fluorescently-label peptide (USBiological Life Science,
Swampscott, MA, USA).
3.1.1. Synthesis of Peptide 1 ([CTVRTSADC])
The linear peptide containing nin amino acids (CTVRTSADC) was synthesized by Fmoc/tBu
solid-phase peptide synthesis. Rink Amide resin (0.3 mmol, 526 mg, 0.57 mmol/g) was swollen in DMF.
The Fmoc group was deprotected using 20% piperidine/DMF un er nitrogen for two times (20 min × 2).
Side chain-protected amino acids (0.9 mmol) were coupled using HBTU (341 mg, 0.9 mmol, 3 equiv) and
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DIPEA (313 µL, 1.8 mmol) in DMF as coupling and activating reagent for 90 min. The Fmoc group was
deprotected using 20% piperidine/DMF under nitrogen twice (20 min × 2). The peptide was assembled
on the resin following coupling of amino acid in the order, e.g., Fmoc-Cys(Trt)-OH (527 mg, 0.9 mmol),
Fmoc-Asp(OtBu)-OH (370 mg, 0.9 mmol), Fmoc-Ala-OH (280 mg, 0.9 mmol), Fmoc-Ser(tBu)-OH
(345 mg, 0.9 mmol), Fmoc-Thr(Trt)-OH (357 mg, 0.9 mmol), Fmoc-Arg(Pbf)-OH (583 mg, 0.9 mmol),
Fmoc-Val-OH (305 mg, 0.9 mmol), Fmoc-Thr(Trt)-OH (357 mg, 0.9 mmol), and Fmoc-Cys(Trt)-OH
(527 mg, 0.9 mmol). Coupling and deprotection cycles were repeated to assemble the sequence of the
linear protected peptide. Then, the side-chain deprotection and cleavage from the resin were carried
out by a freshly prepared cleavage cocktail, trifluoroacetic acid:triisopropylsilane:water (TFA:TIS:H2O;
95:2.5:2.5, v/v/v, 13.5 mL:750 µL:750 µL,15 mL) for 2 h. The crude peptide was precipitated by the
addition of cold diethyl ether (30 mL × 3 times, Et2O) and purified by RP- HPLC on a water XBridge
BEH130 Prep C18 OBD 10 µm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system.
The crude peptide was purified at a flow rate of 10.0 mL/min using a gradient of 0–100% acetonitrile
(0.1% TFA) and water (0.1% TFA) over 60 min on RP-HPLC and then was lyophilized to obtain the
linear peptide. Linear peptide (CTVRTSADC): MALDI-TOF (m/z): C35H64N13O14S2, calcd. [M + H]+
954.4137; found 954.5512. Cyclization of the linear peptide was carried out by exposing the peptide
in 10% DMSO to air at pH 7.4, followed by purification using RP-HPLC. Peptide 1 ([CTVRTSADC]);
MALDI-TOF (m/z): C35H62N13O14S2, calcd. [M + H]+ 952.3980; found 952.4786.
3.1.2. Synthesis of Peptide 8 ([KTVRTSADE])
The linear peptide containing sequence (KTVRTSADE) was synthesized by Fmoc/tBu solid-phase
peptide synthesis. Rink amide resin (0.3 mmol, 526 mg, 0.57 mmol/g) was swelled in DMF. The Fmoc group
was deprotected using 20% piperidine/DMF under nitrogen for two times (20 min × 2). Amino acids were
coupled using HBTU (341 mg, 0.9 mmol, 3 equiv) and DIPEA (313 µL, 1.8 mmol) in DMF as coupling and
activating reagents, respectively. The peptide was assembled on the resin following coupling of amino
acid in the order, e.g., Fmoc-Glu(Phipr)-OH (438 mg, 0.9 mmol), Fmoc-Asp(OtBu)-OH (370 mg, 0.9 mmol),
Fmoc-Ala-OH (280 mg, 0.9 mmol), Fmoc-Ser(tBu)-OH (345 mg, 0.9 mmol), Fmoc-Thr(Trt)-OH (357 mg,
0.9 mmol), Fmoc-Arg(Pbf)-OH (583 mg, 0.9 mmol), Fmoc-Val-OH (305 mg, 0.9 mmol), Fmoc-Thr(Trt)-OH
(357 mg, 0.9 mmol), and Fmoc-Lys(Dde)-OH (479 mg, 0.9 mmol). Coupling and deprotection cycles
were repeated to assemble the sequence of the linear protected peptide. Then, selective side-chain
deprotection were performed in order to remove Phipr (1% TFA/DMF, v/v, 15 min × 3 times) on glutamic
acid and then Dde (2% hydrazine monohydrate/DMF, 20 min × 2 times) to achieve carboxylic group
on the side chain of glutamic acid and amine group at the side chain of lysine side chain amine
group. Cyclization of carboxylic acid and the amino group in the side chain was performed using
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU;
344 mg, 0.9 mmol), ethyl cyano(hydroxyimino)acetate (Oxyma Pure; 136 mg, 0.96 mmol), and DIPEA
(313 µL, 1.8 mmol) in DMF for 3 h. After cyclization was confirmed by MALDI mass, the cleavage of
peptide from the resin was carried out by agitating to a freshly prepared cleavage cocktail, TFA:TIS:H2O
(95:2.5:2.5, v/v/v, 13.5 mL:750 µL:750 µL,15 mL) for 2 h. The crude peptide was precipitated by the
addition of cold diethyl ether (30 mL × 3 times, Et2O). Peptide 8 ([KTVRTSADE]): MALDI-TOF (m/z):
C40H71N14O15, calcd. [M + H]+ 987.5223; found 987.2699.
3.1.3. Synthesis of Peptide 5 (Hydrazine-Glutarate-GG-FK-C6-[CTVRTSADC])
Peptide 1 on solid support from step 3.1.1 was used before final cleavage to attach a spacer
Fmoc-6-Ahx-OH (C6) (157 mg, 0.9 mmol, 3 equiv) in the presence of HBTU (341 mg, 0.9 mmol, 3 equiv)
and DIPEA (313 µL, 1.8 mmol, 6 equiv) in DMF as coupling and activating reagents for 3 days. The resin
was washed, and Fmoc-Lys(Boc)-OH (421 mg, 0.9 mmol) and Fmoc-Phe-OH (348 mg, 0.9 mmol) were
conjugated similarly. Fmoc-Gly-OH (267 mg, 0.9 mmol) was coupled twice and then reacted with
glutaric anhydride (102 mg, 0.9 mmol) to provide a spacer and a carboxylic acid functional group
for further functionalization, respectively. After washing the resin, Boc-hydrazine (396 mg, 3 mmol),
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HOBt (405 mg, 3 mmol), EDC (465 mg, 3 mmol), and DIPEA (1.045 mL, 6 mmol) in dry DMF coupled
for 48 h to provide hydrazine functional group at the N terminal. The resin was washed and cleaved
using cleavage cocktail, TFA:TIS:H2O (95:2.5:2.5, v/v/v, 13.5 mL:750 µL:750 µL,15 mL) for 2 h to afford
linear peptide 5, which after RP-HPLC purification and cyclization in 10% DMSO under air afforded
cyclic peptide 5. MALDI-TOF (m/z): C65H111N21O21S2 calcd. [M + H]+ 1585.7704; found 1585.5270.
3.1.4. Synthesis of Peptide 6 (Hydrazine-Glutarate-GG-VCit-C6-[CTVRTSADC])
The synthesis of peptide 6 was followed by using a similar procedure described in 3.1.3 upto the
coupling of Fmoc-6-Ahx-OH, and then Fmoc-L-citrulline-OH (Cit; 476 mg, 1.2 mmol) and Fmoc-Val-OH
(305 mg, 0.9 mmol) were coupled on the solid phase. After washing and deprotecting Fmoc group, the
resin was further reacted with Fmoc-Gly-OH (twice), glutaric anhydride, and then Boc-hydrazine as
mentioned in the 3.1.3. The cleavage of linear peptide with cleavage cocktail, TFA:TIS:H2O (95:2.5:2.5,
v/v/v, 13.5mL:750µL:750µL, 15 mL), purification by RP-HPLC, and cyclization under 10% DMSO under
air afforded peptide 6. MALDI-TOF (m/z): C61H109N22O22S2, calcd. [M + H]+ 1565.7527; found
1565.5920.
3.1.5. Synthesis of Peptides 19 (C-GFLG-C6-[CTVRTSADC]) and 9 (C-GFLG-C6-[KTVRTSADE])
Both the peptidyl resin from synthesis of peptide 1 (from step 3.1.1) and peptide 8 (from step
3.1.2) were further reacted to attach a Fmoc-6-Ahx-OH (157 mg, 0.9 mmol), Fmoc-Gly-OH (267 mg,
0.9 mmol), Fmoc-Leu-OH (318 mg, 0.9 mmol), Fmoc-Phe-OH (348 mg, 0.9 mmol), Fmoc-Gly-OH
(267 mg, 0.9 mmol), and Fmoc-Cys(Trt)-OH (527 mg, 0.9 mmol) amino acid residues in the separate
peptide synthesis vessel. Coupling and deprotection cycles were repeated to assemble the sequence
of the linear protected peptide followed by cleavage with cleavage cocktail, TFA:TIS:H2O (95:2.5:2.5,
v/v/v, 13.5 mL:750 µL:750 µL,15 mL) for 2 h to afford complete form of peptide 9 and linear form of
peptide 19 which further cyclized using 10% DMSO/H2O. Peptides were purified using RP-HPLC
and characterized using MALDI TOF. Peptide 19 (C-GFLG-C6-[CTVRTSADC]); MALDI-TOF (m/z):
C63H106N19O20S2, calcd. [M + H]+ 1544.6863; found 1544.1794; Peptide 9 (C-GFLG-C6-[KTVRTSADE]);
MALDI-TOF (m/z): C68H113N20O21S, calcd. [M]+ 1577.8110; found 1577.6815.
3.1.6. Synthesis of Conjugate 12 (Dox-hydrazone-glutarate-GG-VCit-C6-[CTVRTSADC])
A solution of dox (16.3 mg, 0.03 mmol) was prepared after dissolving in anhydrous methanol
(2 mL) and was added dropwise to the solution of peptide 5 (47.3 mg, 0.03 mmol) in anhydrous
methanol (1 mL) followed by addition of TFA (0.1%, 3 µL) to acidify the reaction mixture
with continued stirring overnight at room temperature in 5 mL amber glass vial. The solvent
was removed under reduced pressure and conjugate was purified by RP-HPLC. Conjugate 12
(Dox-hydrazone-glutarate-GG-VCit-C6-[CTVRTSADC]); MALDI (m/z): C88H136N23O32S2, calcd. [M +
H]+ 2090.9003; found: 2090.7130.
3.1.7. Synthesis of Conjugate 13 (Dox-s-s-CGFLG-C6-[KTVRTSADE])
First, dox thiol (Dox-SH) was prepared by reacting Dox (25 mg, 43 µmol) with 2-iminothiolane
(2.5 equiv, 107 µmol) in methanol (25 mL) and triethylamine (TEA) (5 equiv, 30 µL) stirred at room
temperature (7 h). The reaction mixture was precipitated by ether (15 mL), and upon decantation,
the precipitant was evaporated using rotary evaporator. The sulfhydryl group of Dox was activated
with dithiodipyridine by reacting Dox-SH (1 equiv, 27 mg, 43 µmol) with 2,2′-dithiodipyridine
(2.5 equiv, 50 mg, 107 µmol) in methanol (0.1% acetic acid, v/v) with stirring at room temperature for
overnight. The resulting precipitate was washed again with cold ether and dried to afford compound
(Dox-S-S-Pyridine). A single peak was detected in the analytical HPLC. Activated Dox compound 10
was coupled with peptide 9 (47 mg, 0.03 mmol) via disulfide bridge using overnight stirring in the
degassed water (5 mL). The solvent was evaporated, and peptide 13 was purified using RP-HPLC.
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Conjugate 13 (Dox-s-s-CGFLG-C6-[KTVRTSADE]); MALDI-TOF (m/z): C99H150N22O32S2, calcd. [M +
H]+ 2223.0227; found 2222.3398.
3.1.8. Synthesis of Conjugate 14 (Doce-βA-thioether-CGFLG-C6-[KTVRTSADE])
Doce-βA-NH2 was first prepared with the stirring of Docetaxel (5 mg, 0.012 mmol), Fmoc-β-alanine
(5.5 mg, 0.062 mmol), using 2-(6-chloro-1-H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium
hexafluorophosphate (HCTU) (14.9 mg, 36 µmol, 3 equiv) and DIPEA (12 µL, 72 µmol, 6 equiv)
in anhydrous DMF (1.5 mL), at room temperature for 90 min. Fmoc was removed by treating with
40% piperidine in DMF (v/v, 10 mL, 20 min), and the resulting peptide was precipitated by ether.
Purification was performed using RP-HPLC followed by lyophilization. Doce-βA-NH2 (10.8 mg,
10 µmol) was reacted with sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
(sulfo-SMCC) (6.5 mg, 15 µmol, 1.5 equiv) in N,N’-diisopropylcarbodiimide (DIC, 8 µL, 5 equiv)
and TEA (8 µL, 6 equiv) using methanol (1 mL), overnight. Docetaxel-βA-SMCC (11) was purified
using RP-HPLC. The Docetaxel-βA-SMCC (7.6 mg, 7 µmol) was dissolved in DMF (5 mL), reacted
with peptide 9 (C-GFLG-C6-[KTVRTSADE]) (12 mg, 76 µmol, 1.08 equiv) in PBS with 20 mM
EDTA at pH 8 (20 mL) for 17 h at room temperature. The formation of conjugated compound
14 (Doce-βA-thioether-C-GFLG-C6-[KTVRTSADE]) was confirmed by mass analysis using MALDI;
MALDI-TOF (m/z): C126H184N23O39S, calcd. [M + H]+ 2675.2842; found 2675.8490.
3.1.9. Synthesis of FAM Conjugate Peptide 17 (FAM-GFLG-C6-[CTVRTSADC])
First, the linear protected peptide 15 (NH2-GFLG-C6-C(Trt)T(tBu)VR(Pbf)T(tBu)S(tBu)AD(OtBu)C
(Trt)) on Rink amide resin was synthesized as described above at 0.2 mmol (350 mg) scale using
Rink amide resin. The peptidyl-resin was washed in DMF (15 mL, 3 × 2 min). The coupling
of 5(6)-carboxyfluorescein diisobutyrate (CFDI, 2.5 equiv, 258 mg), in the presence of HOAt
(2.5 equiv, 68 mg), (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
(PyAOP, 2.5 equiv, 260 mg), and DIPEA (5 equiv, 174 µL) in anhydrous DMF (12 mL) was carried out
for 4.5 h followed by washing with DMF. The deprotection of isobutyrate protection in CFDI was
carried out by agitating the peptidyl resin using piperidine (20%, v/v, 25 mL, 2 × 15 min). The resin
was finally washed with DMF (3 × 3 mL), DCM (3 × 3 mL), and MeOH (3 × 3 mL) and finally dried in
vacuum for 30 min. The fluorescent-labeled peptide was cleaved using TFA:TIS:H2O (95:2.5:2.5, v/v/v,
6.75 mL:375 µL:375 µL) for 2 h. The crude peptide was precipitated with cold diethyl ether (10 mL)
and centrifuged (4500 rpm, 6 min). The solvent was decanted to obtain the precipitant, dried under
nitrogen which was further dissolved in 10% DMSO (100 mL) under dark to form disulfide bridge
between cysteine’s thiol residues under air for overnight. The solvent was evaporated under reduced
pressure to afford viscous peptide precipitate. The precipitate was dissolved in 30% ACN/H2O (v/v,
4 mL), purified by using RP-HPLC, and lyophilized. The mass was confirmed for peptide 17 with
MALDI-TOF (m/z); C81H1N18O25S2, calcd. [M + H]+ 1799.7249; found 1799.9280.
3.1.10. Synthesis of FAM Conjugate Peptide 18 (FAM-GFLG-C6-[KTVRTSADE])
The cyclized protected peptide [KT(tBu)VR(Pbf)T(tBu)S(tBu)AD(OtBu)E] was assembled on
Rink amide resin (0.2 mmol, 350 mg) using steps in Section 3.1.2. The peptidyl resin was washed in
DMF (15 mL, 3 × 2 min) and then solvents were filtered off. Then, Fmoc-Ahx-OH, Fmoc-Gly-OH,
Fmoc-Leu-OH, Fmoc-Phe-OH, and Fmoc-Gly-OH were coupled as mentioned above, followed by
resin washing with DMF (15 mL, 3 × 2 min). The deprotection of N-terminal Fmoc was carried out
using 20% piperidine in DMF (v/v, 2 × 10 min) and then washed with DMF (9 mL, 3 × 2 min) to afford
intermediate peptide 16 (NH2-C(Trt)GFLG-C6-[KT(tBu)VR(Pbf)T(tBu)S(tBu)AD(OtBu)E]-Rink amide
resin). The coupling of 5(6)-carboxyfluorescein diisobutyrate (CFDI, 2.5 equiv, 258 mg), in the presence of
HOAt (2.5 equiv, 68 mg), (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
(PyAOP, 2.5 equiv, 260 mg), and DIPEA (5 equiv, 174 µL) in anhydrous DMF (12 mL) was carried
out to the peptidyl resin for 4.5 h followed by washing with DMF. The deprotection of isobutyrate
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protection in CFDI was carried out by agitating the peptidyl resin using 20% piperidine/DMF (v/v,
25 mL, 2 × 15 min). The resin was finally washed with DMF (3 × 3 mL), DCM (3 × 3 mL), and MeOH
(3 × 3 mL) and finally dried under vacuum for 30 min. The fluorescent-labeled peptide was cleaved
using TFA:TIS:H2O (95:2.5:2.5, v/v/v, 6.75 mL:375 µL:375 µL) for 2 h. The crude peptide was precipitated
with cold diethyl ether (10 mL), centrifuged (4500 rpm, 6 min). The solvent was decanted to obtain the
precipitant to afford viscous peptide precipitate. The precipitate was dissolved in ~30% ACN/H2O (v/v,
4 mL), purified by using RP-HPLC, and lyophilized. The mass was confirmed for peptide 18 with
MALDI-TOF (m/z); C86H118N19O26, calcd. [M + H]+ 1832.8495; found 1832.3740.
3.2. Stability in PBS and Dithiothreitol (DTT)
The stability of peptide–drug conjugate 13 was evaluated in the phosphate buffered saline (PBS).
The pH of PBS was adjusted to 6.8, 7.0, 7.4 using HCl and NaOH as needed. In brief, 250 µL of
1 × PBS was mixed with 45 µL of 0.25 mM Dox-peptide conjugate 13. The mixture was incubated at
37 ◦C in a water bath covered with aluminum foil. An aliquot (40 µL) was removed at different time
intervals, such as 4, 24, and 84 h and analyzed using analytical RP-HPLC at 490 nm. The percentage
of the remained peptide was calculated using the area under the curve (AUC) by integrating the
chromatogram in analytical HPLC. For evaluation of stability in DTT, a solution of DTT (0.120 mM)
was prepared using PBS (pH 7.4). A solution of compounds (1, 8, and 13 at 1 mM) was prepared in PBS
(pH = 7.4). A volume of 45 µL of the peptide was added to 2.250 mL of PBS in a UV-blocking glass vial.
The glass vials were put under nitrogen and stirred using a small magnetic bead. A volume of DTT
(222 mg, 12 equiv) was added to the solution, which was incubated with each peptide sample to obtain
a working concentration of 0.12 mM DTT and 0.010 mM peptide. Aliquots of 200 µL were collected at
different time intervals and analyzed using analytical HPLC vials (0 min was used as controls without
DTT) after quenching the DTT with 10 µL of H2O (pH = 2). The aliquots were run on analytical HPLC
with detection at 214 nm.
3.3. Stability in Human Serum
The stability was performed using 25% human serum. 325 µL of RPMI-1640 media was incubated
with 125 µL of human serum at 37 ◦C in a water bath. Then 50 µL of 125 µM of conjugate 13 was added
to the RPMI and serum. The control experiment was performed without conjugate using an aqueous
5% DMSO. Several aliquots (55 µL) were removed at 2, 5, 10, 15, 30, 60, 90, and 120 min. The aliquots
were added to 120 µL of cold methanol to precipitate the serum proteins with vigorous mixing using
vortex and kept at ice for 10 min. Then, the samples were centrifuged at 17× g (13,300 rpm) for 10 min
to get a pellet of the insoluble peptide. The supernatant was collected and analyzed on analytical
HPLC, as mentioned before.
3.4. Hydrolysis Studies with Cathepsin Enzyme
Human cathepsin B (CTSB, Lot # CB2016-02 from Athens Research, Athens, GA, USA) was used to
hydrolyze the cathepsin linker GFLG in conjugated peptide 13. A stock solution of cathepsin B enzyme
(0.434 µg/µL) was prepared using 50 mM acetate (pH 5.0) buffer with 1 mM EDTA. The activation
buffer was separately prepared using 30 mM DTT and 15 mM EDTA in H2O. An aliquot of 2.25 µL of
cathepsin B stock was activated with 5 µL of activation buffer for 15 min at room temperature then
diluted with 1.185 mL of acetate buffer and aliquoted into different tubes with 200 µL each. Further
8 µL of 1 mM of conjugated peptide 13 was added to aliquots and incubated for various time intervals.
Then, the reaction was quenched by boiling to denature cathepsin B for 10 min. A 400 µL of cold
methanol was added to precipitate the proteins followed by centrifugation of sample 17× g (13,300 rpm)
for 10 min. A supernatant (500 µL) was collected, evaporated, and reconstituted with 300 µL of HPLC
solvent A (H2O with 0.1% TFA). The eluent fraction from HPLC was further collected and analyzed
using MALDI-TOF mass spectrometry to confirm the hydrolysis of the conjugate.
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3.5. Cell Culture
Human epithelial prostate cell line (RWPE-1, ATCC No. CRL-11610), human prostate cancer cell
line (Human prostate carcinoma DU-145, ATCC No. HTB-81), human adenocarcinoma PC3, ATCC No.
CRL-1435), androgen-sensitive human prostate adenocarcinoma cells (LNCaP, ATCC No. CRL-1740),
and castration-resistant LNCaP-derived C4-2 (ATCC No. CRL-1595) were purchased from American
Type Culture Collection (ATCC), Manassas, VA, USA. All the media, serum, and antibiotics were
bought from American Type Culture Collection (ATCC) (Manassas, VA, USA) and Sigma life-science
(St. Louis, MO, USA). Keratinocytes SFM (1×) with EGF + BPE was bought from Gibco life technologies
(Thermo Fisher Scientific), Gaithersburg, MD, USA. CellTiter 96 was bought from Promega, Madison,
WI, USA. Dithiothreitol (DTT) was bought from Thermo Fisher scientific, Carlsbad, CA, USA, and
TGF-β was bought from Abcam, Boston, MA, USA.
3.5.1. Cell Viability Assays using MTS
Cell-proliferation assay using MTS reagent was conducted against five cell lines (RWPE-1, PC3,
DU-145, LNCaP, and, C4-2). Cells were seeded into 96-well plates (5 × 103 cells for all the cells) and
incubated with 100 µL of complete medium (RPMI-1640 for RWPE-1, DU-145, LNCaP, and C4-2;
DMEM for PC3) overnight at 37 ◦C with 5% CO2. Various concentrations (0, 0.06, 0.6, 6, 60, 600 µM) of
the peptide solution (20 µL) were added to cells to yield the final concentrations of peptide (0, 0.01,
0.1, 1, 10, 100 µM). The cells were kept in an incubator (37 ◦C, 5% CO2) for 24, 48, or 72 h accordingly
for different treatment time responses. Then, a CellTiter 96 aqueous solution (20 µL) was added to
each well and incubated for 4 h under the same condition. The absorbance was obtained at 490 nm
using SpectraMax M2 microplate reader to detect the formazan product. Wells containing cells in
the absence of any peptide were used as a control. The percentage of cell viability was calculated by
[(OD value of cells treated with the test mixture of compounds) − (OD value of culture medium)]
/ [(OD value of control cells) − (OD value of culture medium)] × 100%. For other time-dependent
experiments, compounds (5 µM) were added to each well in triplicate and kept for 24, 48, and 72 h at
37 ◦C in a 5% CO2 incubator. Cell viability was determined by measuring the absorbance at 490 nm
using SpectraMax M2 microplate spectrophotometer, as mentioned above.
3.5.2. Overexpression of EDB-FN using TGF-β
To compare the cytotoxicity of compounds using treatment of TGF-β, the cells were culture, and
8000 cells (RPWE-1, PC3, DU-145, LNCap, and C4-2) were added in 120 µL per well with TGF-β
treatment. Cells were exposed to TGF-β at 10 ng/mL for 3 days. Then cells were seeded in the
corresponding medium (DMEM containing 10% FBS and 1% penicillin–streptomycin for DU-145,
LNCaP, and PC3; keratinocyte containing 0.1% FBS without antibiotics for RWPE-1), 24 h prior to the
experiment. Then, MTS assay was followed up, as mentioned in 3.5.1.
3.5.3. Confocal Microscopy
Prostate cancer cell line (C4-2) was grown in RPMI medium containing 10% fetal bovine serum and 1%
penicillin/streptomycin at the 37 ◦C in a 5% CO2 incubator. The culture medium was changed every 2–3 days
until confluency was reached to 80%. Each cells group was treated with 5µg of fluorescence-tagged peptides
(17 and 18) for 12 h. A set of control groups was also prepared, which was not treated with peptides. Then
all cells were fixed with 4% paraformaldehyde for 10 min and washed for 10 min (3 times with PBS). The
cells were blocked in 1% FBS/PBS for 10 min and washed for 10 min (3 times with PBS). To target EDB-FN
on the cell surface, the cells were incubated with a mouse monoclonal anti-fibronectin antibody (Abcam,
Cambridge, MA, USA) (1:1000 dilution using 1% FBS/PBS) overnight at the 4 ◦C. The cells were washed
for 10 min (3 times with PBS), and a Texas red-conjugated anti-mouse secondary antibody was used in 1%
FBS/PBS (5:1000 dilution) at the room temperature for 1 h. Then cells were washed for 10 min (3 times with
PBS), and at the end, nuclei were stained using DAPI and covered with coverslips. Representative images
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of cells were captured using a standard confocal microscope (Nikon Eclipse Ti-E, Nikon Instruments Inc.,
Melville, NY, USA) at 60×magnification, and the images were processed for binary contrast quantification.
4. Conclusions
In conclusion, the synthesis and optimization of EDB-FN ligands were achieved using Fmoc/tBu
solid phase synthesis. The lactam cyclized ligand [KTVRTSADE] 8 showed higher stability under
redox condition (8 h) as compared to disulfide cyclized ligand [CTVRTSADC] 1 (2.6 min). A half-life of
11.8 min was detected for Dox conjugate 13 during treatment with 25% serum. A cathepsin enzyme
based linkers were introduced in Dox/Doce conjugates (13 and 14), which releases the drug from
conjugate within 5 min after treatment with cathepsin enzyme. The antiproliferative activity of Dox
conjugate 13 exhibited comparable or the similar antiproliferative activity versus Dox alone or physical
mixture in 72 h in all the cell lines (RWPE-1, PC3, DU-145, and LNCaP). The Doce conjugate 14 showed
mild or no activity which might be due to the lack of hydrolysis of the drug from conjugate in all the
cell lines. The TGF-β treatment in C4-2 cell lines demonstrates the effect of overexpression of EDB-FN
on cell viability. Confocal microscopy demonstrated localization of ligands at EDB-FN in C4-2 cell line.
The peptide 18 containing lactam cyclization showed higher targeting at EDB-FN in C4-2 cell lines as
compared to peptide 17 containing disulfide cyclization. These studies provide a better understanding
for designing peptide–drug conjugate to be used as a chemotherapeutic agent against PCa.
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